Summary
This prediction ended on 07.06.18 with a price of €27,600,000. With a performance of -9.21%, the BUY prediction by melinda finished with a loss. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Neovacs | - | - | - | - |
iShares Core DAX® | -1.347% | 3.576% | 14.229% | 18.356% |
iShares Nasdaq 100 | 1.169% | 7.020% | 35.388% | 58.850% |
iShares Nikkei 225® | -0.327% | -0.673% | 8.618% | 6.718% |
iShares S&P 500 | 0.510% | 4.445% | 28.019% | 49.406% |
According to melinda what are the pros and cons of Neovacs for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Neovacs diskutieren
Neovacs: Beginn der Spekulation vor klinischen Ergebnissen für LUPUS?
(Vom Mitglied beendet)